Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emi-Le in Participants with Solid Tumors
NCT05377996Phase 2Recruiting
- Sponsor
- Day One Biopharmaceuticals
- Start
- Aug 2022
- Primary completion
- Feb 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of emiltatug ledadotin in solid tumor, triple-negative breast cancer (TNBC), breast cancer and 5 more, sponsored by Day One Biopharmaceuticals. Primary endpoints: Dose-Limiting Toxicities at 17 months, Adverse Events at 3 years and 1 more. Started Aug 2022; status: recruiting.
02
Drugs
emiltatug ledadotin
03
Conditions
solid tumortriple-negative breast cancer (TNBC)breast cancerendometrial cancer (EC)ovarian cancer
Beyond the preview
Go deeper on NCT05377996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05377996.